Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2033230284
JPRN-jRCT2033230284
Recruiting
未知

ong-term observational study of Gene Therapy for Sporadic ALS

Morita Mitsuya0 sites6 target enrollmentAugust 9, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSporadic amyotrophic lateral sclerosis (Sporadic ALS)

Overview

Phase
未知
Intervention
Not specified
Conditions
Sporadic amyotrophic lateral sclerosis (Sporadic ALS)
Sponsor
Morita Mitsuya
Enrollment
6
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 9, 2023
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Morita Mitsuya

Eligibility Criteria

Inclusion Criteria

  • •Patients who enrolled in the Phase I/II Study of Gene Therapy for Sporadic ALS, and who completed or discontinued the study.

Exclusion Criteria

  • •\-Patients who are judged by the investigator or subinvestigator to be inappropriate to participate in this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
ong-term observational study of Gene Therapy for AADC deficiencyAromatic L-amino acid decarboxylase deficiency
JPRN-jRCT2033220245Yamagata Takanori1
Recruiting
Not Applicable
ong-term observational study of Gene Therapy for Parkinson's diseaseParkinson's disease
JPRN-jRCT2033220367akajima Takeshi12
Active, not recruiting
Phase 1
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseSickle Cell DiseaseMedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2019-000331-63-FRbluebird bio, Inc.35
Active, not recruiting
Phase 1
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell Disease
EUCTR2019-000331-63-NLbluebird bio, Inc.35
Active, not recruiting
Phase 1
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseSickle Cell DiseaseMedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2019-000331-63-ITBLUEBIRD BIO, INC.35